First Manhattan’s Cellebrite CLBT Stock Holding History

First Manhattan’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-37	Closed	-$283	–	1459
2023 Q3	$283	Buy	+37	New	+$278	﹤0.01%	1407

Other funds holding CLBT

IIGPLP

IGP Investments (G.P.L.P.) Herzliya, Israel $6.25M AUM 18.64% 1-Year Est. Return

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

First Manhattan's CLBT Position: Q4 2023 in Review

First Manhattan sold out of Cellebrite (CLBT) in Q4 2023, closing a stake of 37 shares — an estimated $283 sold.

First Manhattan first reported a position in CLBT in Q3 2023 and held it in 1 quarter. The position peaked at $283 in Q3 2023. 116 funds tracked by Wall St. Rank hold CLBT as of Q4 2023.

First Manhattan reported no remaining Cellebrite position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 37 Cellebrite shares in Q4 2023, an estimated $283.
First Manhattan first reported a position in Cellebrite in Q3 2023 and held it in 1 quarter.
First Manhattan's Cellebrite position peaked at $283 in Q3 2023.
116 funds tracked by Wall St. Rank held Cellebrite as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.